Mandate

Vinge has advised Tobii in connection with the listing of Tobii Dynavox

Vinge has advised Tobii and Tobii Dynavox in connection with the distribution of the shares in Tobii Dynavox to the shareholders in Tobii as well as the listing of Tobii Dynavox’s ordinary shares on Nasdaq Stockholm. The prospectus was published 23 November 2021 and the first day of trading on Nasdaq Stockholm was 9 December 2021.

Tobii Dynavox is the global leader in assistive technology for communication. The company’s custom designed solutions enable people with disabilities such as cerebral palsy, ALS and spinal cord injury to communicate with a voice of their own, develop literacy skills and live more independently. To date, hundreds of thousands of people worldwide have benefited from their integrated solutions, which include hardware, software, clinically developed language systems, special education tools, training, and dedicated support. The company offers an extensive funding support system to reach as many people as possible. Headquartered in Sweden, Tobii Dynavox employs around 500 people with offices in the US, the UK, Norway and China, and reselling partners in 60+ countries.

Vinge’s team consisted of Jesper Schönbeck, Amanda Knutsson, Joel Magnusson, Emil Lindwall, Pernilla Björklund, Henrik Wastensson, Victor Ericsson and Emelie Svanberg,Maria Dahlin Kolvik, Christina Odengran, Ellinor Wargenbrant, Eléonore Friberg, Jolene Reimerson and Viktoria Owetz Leyva.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024